Rapid AI Gets FDA OK for Perfusion Imaging in the Angiography Suite

RapidAI has achieved U.S. Food and Drug Administration (FDA) 510(k) clearance for its AngioFlow by Rapid AI solution, which offers perfusion imaging analysis in the interventional suite.
 
AngioFlow by RapidAI draws on validated deep clinical artificial intelligence (AI) for clear, easily interpretable qualitative perfusion maps in minutes to help assess ischemic change in brain regions with lowered cerebral blood flow.
 
According to the company, AngioFlow boosts operational efficiency and financial value by reducing redundant imaging and possible saving time in patient care. Imaging at a referring facility allows evaluating the need for further scans in the interventional suite, quickening clinical decisions and reducing imaging that isn’t needed—especially helpful in rural facilities and large hospital networks.
 
“We are pleased to expand our stroke AI imaging portfolio, the broadest in the industry, to include this new module. With AngioFlow by RapidAI, we can now support stroke AI imaging along the entire patient pathway, from the initial non-contrast CT scan all the way to the interventional suite,” said Karim Karti, CEO of RapidAI. “Already registered and used in Japan and Europe, we believe this technology will make a significant difference in the lives of U.S. stroke patients.”
 
“AngioFlow by RapidAI will allow physicians to assess the need for additional imaging immediately in the interventional suite. By avoiding unnecessary scans, stroke patients can receive the timely care that can be the difference between being able to walk out of a hospital to their homes versus being discharged to a skilled nursing facility,” added Abhishek Singh, MD, DABPN, DUCNS at the Creighton University School of Medicine in Omaha, Nebraska.